RxDoctor Payments Data

Sam Hamade, MD

Pulmonary Disease · Warren, MINPI 1588752422

Payments from drug & device makers

$635in general payments, 2019–2025

Across 28 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viatris Specialty LLC$118
  • Sanofi-aventis U.S. LLC$100
  • GSK$67
  • Sanofi$55
  • Verona Pharma, Inc.$34
  • AstraZeneca$29
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$53584%
  • Education$10016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$635 in reported general payments places this provider in the 35th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$159,319
Medicare patients
387
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter366$356,795
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$18,747
Combivent RespimatIpratropium/Albuterol Sulfate27$16,678
Fluticasone-SalmeterolFluticasone Propion/Salmeterol71$12,409
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$10,508
Spiriva RespimatTiotropium Bromide14$8,087
Advair HfaFluticasone Propion/Salmeterol19$7,861
Albuterol Sulfate HfaAlbuterol Sulfate179$7,631
Incruse ElliptaUmeclidinium Bromide14$6,217
Breo ElliptaFluticasone/Vilanterol16$6,119
Ventolin HfaAlbuterol Sulfate88$5,105
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$4,258
SymbicortBudesonide/Formoterol Fumarate16$3,845
BreynaBudesonide/Formoterol Fumarate18$3,522
Roflumilast22$1,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$67$387,877425 claims
Boehringer IngelheimCombivent Respimat, Stiolto Respimat, Spiriva Respimat$21$35,27356 claims
AstraZenecaSymbicort$29$3,84516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →